Form 4: Bioxytran CEO David Platt Reports Changes in Beneficial Ownership

David Platt, CEO of Bioxytran, Inc., reports changes in his beneficial ownership of the company's preferred stock due to a return of shares to treasury and shares issued as payment for the sale of NDPD Pharma to Bioxytran.

Summary

• On October 25, 2024, David Platt, CEO of Bioxytran, Inc. (BIXT), filed a Form 4 detailing changes in his beneficial ownership of the company's securities.
• 14,085,410 preferred shares were returned to the treasury and cancelled at a price of $0.285.
• 11,190,077 preferred shares were acquired at a price of $0.545 as payment for the sale of NDPD Pharma to Bioxytran.
• Following these transactions, Platt directly owns 19,795,532 preferred shares.
• The total holdings in BIXT by NDPD Pharma, Inc., an affiliate whose beneficial ownership includes Mike Sheikh, Ola Soderquist, and David Platt, were consolidated under indirect ownership in Davis Platt's filing.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing primarily reports transactions related to beneficial ownership changes. The acquisition of shares could be seen as slightly positive, while the return of shares to treasury could be seen as slightly negative.

Positives

• The acquisition of shares as payment for the sale of NDPD Pharma to Bioxytran could be seen as a positive sign of the company's growth strategy.

Negatives

• The return of 14,085,410 preferred shares to the treasury and cancellation could be seen as a negative, depending on the reason for the cancellation.

Risks

• Changes in beneficial ownership can sometimes indicate shifts in company strategy or financial health, requiring further investigation.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. This filing indicates changes in David Platt's ownership stake in Bioxytran.

Related Party Transactions

• The acquisition of shares is related to the sale of NDPD Pharma to Bioxytran, indicating a related-party transaction.

Stakeholder Impact

• The changes in beneficial ownership may be of interest to shareholders as it reflects the CEO's stake in the company.

Key Dates

Keywords

Bioxytran, BIXT, David Platt, beneficial ownership, Form 4, NDPD Pharma, preferred shares, acquisition, treasury shares